$ cat ./records/announced-168-million-to-fund-a-new-generation-of-malaria-vaccine-2008.txt
Announced $168 million to fund a new generation of malaria vaccines targeting higher efficacy
[RECORD.TXT] · cat --full
Bill Gates announced $168 million in new grants to develop a second generation of malaria vaccines beyond RTS,S, funding researchers exploring novel antigen targets, adjuvant combinations, and transmission-blocking approaches designed to achieve efficacy levels exceeding the 30–40% range of first-generation candidates. The investment reflected a long-term strategy: accepting that RTS,S alone would not be sufficient for eradication and funding the pipeline that would be needed a decade later. The grants supported teams at institutions across Africa, Europe, and North America.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Testified before Congress calling for H-1B reform, elimination of per-country green card limits, and fast-track residency for STEM graduates
Next →
Gates Foundation Funds BioCassava Plus Project to Develop Nutritionally Enhanced Cassava for Sub-Saharan Africa
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.